Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders

Cell Cycle

Volumn 5, Issue 15, 2006, Pages 1621-1628

  De Nigris, Filomena ^a   Balestrieri, Maria Luisa ^a   Napoli, Claudio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; c Myc; Cancer; IGF; Ras

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 4126; CGP 69846A; CISPLATIN; FLAVONOID; GERANYLGERANYLTRANSFERASE 1 INHIBITOR; INDAZOLE DERIVATIVE; INX 6295; L 778123; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NCS 685403; NSC 685403; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SILIBININ; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TAMOXIFEN; TIPIFARNIB; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOPHAGY; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; CORONARY ARTERY ATHEROSCLEROSIS; DRUG BIOAVAILABILITY; DRUG MECHANISM; HUMAN; KIDNEY CANCER; LUNG CANCER; MELANOMA; MYELOMA CELL; OVARY CANCER; PROSTATE CANCER; RESTENOSIS; REVIEW; STEM CELL MOBILIZATION; TRANSCRIPTION INITIATION; TRANSLATION INITIATION; TUMOR XENOGRAFT; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

MAMMALIA;

EID: 33748098986     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.15.3138     Document Type: Review

References (102)

1. Napoli C, Lerman LO, de Nigris F, Sica V. c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases? Neoplasia 2002; 4:185-90.
2. Herrmann J, Lerman LO, Mukhopadhyay D, Napoli C, Lerman A. Angiogenesis in atherogenesis and carcinogenesis. Arterioscler Thromb Vasc Biol 2006; in press.
3. Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63:403-13.
4. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973; 70:1753-6.
5. Penn A, Garte SJ, Warren L, Nesta D, Mindich B. Transforming gene in human atherosclerotic plaque DNA. Proc Natl Acad Sci U S A 1986; 83:7951-5.
6. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996; 225:186-90.
7. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL Jr. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997; 100:2182-8.
8. Casalone R, Granata P, Minelli E, Portentoso P, Giudici A, Righi R, Castelli P, Socrate A, Frigerio B. Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum Genet 1991; 87:139-43.
9. Andreassi MG, Botto N, Colombo MG, Biagini A, Clerico A. Genetic instability and atherosclerosis: can somatic mutations account for the development of cardiovascular diseases? Environ Mol Mutagen 2000; 35:265-9.
10. Chen S, Qiong Y, Gardner DG. A role for p38 mitogen-activated protein kinase and c-Myc in endothelial dependent rat aortic smooth muscle cell proliferation. Hypertension 2006; 47:252-8.
11. de Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G, Lerman A, Lerman LO, Napoli C. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle 2003; 2:325-8.
12. Mitani H, Takimoto M, Bandoh T, Kimura M. Increases of vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol 2000; 387:313-9.
13. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001; 61:8340-6.
14. de Nigris F, Youssef T, Ciafre S, Franconi F, Anania V, Condorelli G, Palinski W, Napoli C. Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. Circulation 2000; 102:2111-7.
15. de Nigris F, Lerman LO, Rodriguez-Porcel M, De Montis MP, Lerman A, Napoli C. c-Myc activation in early coronary lesions in experimental hypercholesterolemia. Biochem Biophys Res Commun 2001; 281:945-50.
16. K C S, Carcamo JM, Golde DW. Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-Myc. Mutat Res 2006; 593:64-79.
17. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20:2175-83.
18. Secombe J, Pierce SB, Eisenman RN. c-Myc: a weapon of mass destruction. Cell 2004; 117:153-6.
19. Prober Da, Edgar BA. Ras1 promotes cellular growth in the Drosophila wings. Cell 2000; 100:435-46.
20. Karim FD, Rubin GM. Ectopic expression of activated Ras1 induces hyperplastic growth and increased cell death in Drosophila imaginal tissues. Development 1998; 125:1-9.
21. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. c-Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387:422-6.
22. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4:677-85.
23. Li F, Munchhof AM, White HA, Mead LE, Krier TR, Fenoglio A, Chen S, Wu X, Cai S, Yang FC, Ingram DA. Neurofibromin is a novel regulator of Ras induced signals in primary vascular smooth muscle cells. Hum. Mol Genet 2006; [Epub ahead of print].
24. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, Komuro I. Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation 2003; 108:2264-9.
25. Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 2001; 132:1531-41.
26. George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 2002; 105:2416-22.
27. Miura S, Matsuo Y, Kawamura A, Saku K. JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways. Atherosclerosis 2005; 182:267-75.
28. Wu CH, Lin CS, Hung JS, Wu CJ, Lo PH, Jin G, Shyy YJ, Mao SJ, Chien S. Inhibition of neointimal formation in porcine coronary artery by a Ras mutant. J Surg Res 2001; 99:100-6.
29. Potenza N, Vecchione C, Notte A, De Rienzo A, Rosica A, Bauer L, Affuso A, De Felice M, Russo T, Poulet R, Cifelli G, De Vita G, Lembo G, Di Lauro R.Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice EMBO Rep 2005; 6:432-7.
30. Conti E, Pitocco D, Capoluongo E, Zuppi C, Ghirlanda G, Crea F, Andreotti F. IGF-1 and macrovascular complications of diabetes. Diabetes Care 2003; 26:1653-4.
31. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75.
32. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and metaregression analysis. Lancet 2004; 363:1346-53.
33. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-18.
34. Wu Y, Cui K, Miyoshi K, Hennighausen L,Green JE, Setser J, LeRoith D, Yakar S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63:4384-8.
35. Williams AC, Smartt H, H-Zadeh AM, Macfarlane M, Paraskeva C, Collard TJ. Insulinlike growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ 2006; [Epub ahead of print]
36. Garcia de la Torre N, Wass JA, Turner HE. Angiogenic effect of somatostatin analogous. Clin Endocrinol 2002; 57:425-41.
37. Durai R, Davies M, Yang W, Yang SY, Seifalian A, Goldspink G, Winslet M. Biology of insulin-like growth factor binding protein-4 and its role in cancer. Int J Oncol 2006; 28:1317-25.
38. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 2005; 92:2097-101.
39. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75.
40. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C & Capeau J. Insulin and IGF-1 stimulate the β-catenin pathway through two signaling cascades involving GSK-3β inhibition and Ras activation. Oncogene 2001; 20:252-9.
41. Andre F, Janssens B, Bruyneel E, van Roy F, Gespach C, Mareel M, Bracke M. α-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. Oncogene 2004; 23:1177-86.
42. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Research 1998; 58,:4008-14.
43. Slomiany MG, Rosenzweig SA. Hypoxia inducible factor-1 (HIF-1) dependent and independent regulation of insulin-like growth factor-1 (IGF-1) stimulated vascular endothelial growth factor (VEGF) secretion. J Pharmacol Exp Ther 2006; [Epub ahead of print]
44. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM,Semenza GL. Insulin- like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277:38205-11.
45. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research 2002; 62:1030-35.
46. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res 2000; 86:125-30.
47. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev 2005; 13:35-9.
48. Sandhu MS. Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 2005; 9:44-54.
49. Napoli C. Oxidation of LDL, atherogenesis, and apoptosis. Ann NY Acad Sci 2003; 1010:698-709.
50. Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, Fallon JT, Fuster V, Badimon JJ. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation 2003; 107:1658-63.
51. Schini-Kerth VB. Dual effects of insulin-like growth factor-1 on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999; 22:82-8.
52. Conti E, Andreotti F, Sestito A, Riccardi P, Menini E, Crea F, Maseri A, Lanza GA. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol 2002; 89:973-5.
53. Oltman CL, Kane NL, Gutterman DD, Bar RS, Dellsperger KC. Mechanism of coronary vasodilation to insulin and insulin-like growth factor-1 is dependent on vessel size. Am J Physiol Endocrinol Metab 2000; 279:E176-81.
54. Nakazawa T, Chiba T, Kaneko E, Yui K, Yoshida M, Shimokado K. Insulin signaling in arteries prevents smooth muscle apoptosis. Arterioscler Thromb Vasc Biol 2005; 25:760-5.
55. Spies M, Nesic O, Barrow RE, Perez-Polo JR, Herndon DN. Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound. Gene Ther 2001; 8:1409-15.
56. Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor-1. Kidney Int 1991; 39:333-5.
57. Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-1 cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000; 11:69-76.
58. Isenovic ER, Meng Y, Divald A, Milivojevic N, Sowers JR. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin and insulin-like growth factor-1 modulation of nitric oxide synthesis in vascular smooth muscle cells. Endocrine 2002; 19:287-92.
59. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003; 157:25-31.
60. Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003; 16:754-60.
61. Gonzalez-Timon B, Gonzalez-Munoz M, Zaragoza C, Lamas S, Melian EM. Native and oxidized low density lipoproteins oppositely modulate the effects of insulin-like growth factor I on VSMC. Cardiovasc Res 2004; 61:204-5.
62. LaBelle EF, Tulenko TN. LDL, IGF-1, and VSMC apoptosis: linking atherogenesis to plaque rupture in vulnerable lesions. Cardiovasc Res 2004; 61:204-5.
63. Patel VA, Zhang QJ, Siddle K, Soos MA, Goddard M, Weissberg PL, Bennett MR. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 2001; 88:895-902.
64. Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol 2001; 33:1777-89.
65. Zaina S, Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. Curr Opin Lipidol 2003; 14:483-9.
66. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87.
67. Ocana A, Rodriguez CA, Cruz JJ. Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. Clin Transl Oncol 2005; 7:99-100.
68. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7.
69. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. c-Myc inactivation uncovers pluripotent differentiation and tumor dormancy in hepatocellular cancer, Nature 2004; 431:1112-7.
70. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: Targeting the dark side of c-Myc. European Journal of Cancer 2005; 41:2485-501.
71. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-Myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62:3126-31.
72. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G. c-Myc Antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 58:283-9.
73. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 2003; 14:39-47.
74. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-Myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003; 9:2510-19.
75. Devi GR, Beer TM, Corless CL, AroraV, Weller DL, Iversen PL. In vivo bioavailability and pharmacokinetics of a c-Myc antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 2005; 11:3930-8.
76. Leonetti C, Biroccio A, Benassi B, Stringaro A, Stoppacciaro A, Semple SC, Zupi G. Encapsulation of c-Myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther 2001; 8:459-68.
77. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Antitumour efficacy of bcl-2 and c-Myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res 2005; 11:1990-8.
78. Qin G, Zhang Y, Cao W, An R, Gao Z, Li G, Xu W, Zhang K, Li S. Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides. Eur J Nucl Med Mol Imaging 2005; 32:6-14.
79. Khanna A. Concerted effect of transforming growth factor-β, cyclin inhibitor p21, and c-Myc on smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 2004; 286:H1133-40.
80. Kipshidze N, Tsapenko M, Iversen P, Burger D. Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opin Biol Ther 2005; 5:79-89.
81. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serrus PW. Local intracoronary administration of antisense oligonucleotide against c-Myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALIC) trial. J Am Coll Cardiol 2002; 39:281-7.
82. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7:R220-8.
83. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23:709-17.
84. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-Myc gene. Nucl Acids Res 2004; 32:2396-410.
85. Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. The cationic porphyrin TMPyP4 down-regulates c-Myc and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002; 1:565-73.
86. Lemarteleur T, Gomez D, Paterski R, Mandine E, Mailliet P, Riou JF. Stabilisation of the c-Myc gene promoter quadruplex by specific ligands' inhibitors of telomerase. Biochem Biophys Res Commun 2004; 323:802-8.
87. Seenisamy J, Bashyam S, Gokhale V, Vankayalapati H, Sun D, Siddiqui-Jain A, Streiner N, Shin-Ya K, White E, Wilson WD, Hurley LH. Design and synthesis of an expanded porphyrin that has selectivity for the c-Myc G-quadruplex structure. J Am Chem Soc 2005; 127:2944-59.
88. Soucek L, Nasi S, Evan GI. Omomyc expression in skin prevents c-Myc-induced papillomatosis. Cell Death Differ 2004; 11:1038-45.
89. Jiang G, Bi K, Tang T, Wang J, Zhang Y, Zhang W, Ren H, Bai H, Wang Y. Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by c-Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO. Int Immunopharmacol 2006; 6:1204-13.
90. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larranaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006; 13:593-605.
91. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13:583-92.
92. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005; 7:R570-9.
93. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006; [Epub ahead of print]
94. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: Bench to bedside. Mol Carcinog 2006; 45:436-42.
95. Peng CY, Pan SL, Guh JH, Liu YN, Chang YL, Kuo SC, Lee FY, Teng CM. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost 2004; 92:1232-9.
96. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renalcell cancer: a review. Ann Oncol 2006; [Epub ahead of print]
97. George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 2002; 105:2416-22.
98. Brunner TB, Hahn SM, Gupta AK et al. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63:5656-8.
99. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. The Oncologist 2005; 10:565-78.
100. Peterson YK, Kelly P, Weinbaum CA, Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 2006; 281:12445-50.
101. Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signaling in multiple myeloma cells. Br J Haematol 2005; 130:912-25.
102. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. Clin Oncol 2005; 23:5099-107.